메뉴 건너뛰기
Clinical Lymphoma and Myeloma
Volumn 7, Issue 3, 2006, Pages 233-235
Bortezomib-induced tumor lysis syndrome in multiple myeloma
Author keywords

Dexamethasone; Hemodialysis; Proteasome
Indexed keywords

ALLOPURINOL; BICARBONATE; BORTEZOMIB; DEXAMETHASONE; FUROSEMIDE; RECOMBINANT ENZYME; RECOMBINANT URATE OXIDASE; SODIUM; UNCLASSIFIED DRUG;
EID: 34548012379     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.064     Document Type: Article
Times cited : (40)
References (15)
  • 1
    • 0034744148 scopus 로고    scopus 로고
    • Acute tumor lysis syndrome
    • Altman A. Acute tumor lysis syndrome. Semin Oncol 2001; 28(2 suppl 5):3-8.
    • (2001) Semin Oncol , vol.28 , Issue.2 SUPPL. 5 , pp. 3-8
    • Altman, A.1
  • 2
    • 37949022385 scopus 로고    scopus 로고
    • Laboratory investigations
    • In: Mehra J, Singhal S, eds London: Martin Dunitz
    • San Miguel JF, Almeida J, Orfao A. Laboratory investigations. In: Mehra J, Singhal S, eds. Myeloma. London: Martin Dunitz; 2002:243-268.
    • (2002) Myeloma , pp. 243-268
    • San Miguel, J.F.1    Almeida, J.2    Orfao, A.3
  • 3
    • 0033060286 scopus 로고    scopus 로고
    • Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma
    • Fassas AB, Desikan KR, Siegel D, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 1999; 105:938-941.
    • (1999) Br J Haematol , vol.105 , pp. 938-941
    • Fassas, A.B.1    Desikan, K.R.2    Siegel, D.3
  • 4
    • 0034896045 scopus 로고    scopus 로고
    • Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy
    • van de Kerkhof JJ, Peters WG, Visser J, et al. Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy. Neth J Med 2001; 59:83-85.
    • (2001) Neth J Med , vol.59 , pp. 83-85
    • van de Kerkhof, J.J.1    Peters, W.G.2    Visser, J.3
  • 5
    • 0037089681 scopus 로고    scopus 로고
    • Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma
    • Cany L, Fitoussi O, Boiron JM, et al. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol 2002; 20:2212.
    • (2002) J Clin Oncol , vol.20 , pp. 2212
    • Cany, L.1    Fitoussi, O.2    Boiron, J.M.3
  • 6
    • 0033152760 scopus 로고    scopus 로고
    • Proteasome inhibitors: A novel class of potent and effective antitumor agents
    • Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
    • (1999) Cancer Res , vol.59 , pp. 2615-2622
    • Adams, J.1    Palombella, V.J.2    Sausville, E.A.3
  • 7
    • 0035300479 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells
    • Hideshima T, Richardson R Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
    • (2001) Cancer Res , vol.61 , pp. 3071-3076
    • Hideshima, T.1    Richardson, R.2    Chauhan, D.3
  • 8
    • 0037973279 scopus 로고    scopus 로고
    • A phase II study of bortezomib in relapsed and refractory myeloma
    • Richardson PG, Barlogie B, Berenson J, et al. A phase II study of bortezomib in relapsed and refractory myeloma. N Engl J Med 2003; 348:2609-2617.
    • (2003) N Engl J Med , vol.348 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 9
    • 0141836171 scopus 로고    scopus 로고
    • Treatment of multiple myeloma
    • Singhal S. Treatment of multiple myeloma. BMJ 2003; 327:575-576.
    • (2003) BMJ , vol.327 , pp. 575-576
    • Singhal, S.1
  • 10
    • 1942442042 scopus 로고    scopus 로고
    • Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma
    • (Abstract #5273)
    • Mehra J, Jakob G Singhal S, et al. Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 2003; 102:386b (Abstract #5273).
    • (2003) Blood , vol.102
    • Mehra, J.1    Jakob, G.2    Singhal, S.3
  • 11
    • 5644266386 scopus 로고    scopus 로고
    • Tumour lysis syndrome in multiple myeloma after bortezomib (Velcade) administration
    • Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (Velcade) administration. J Cancer Res Clin Oncol 2004; 130:623-625.
    • (2004) J Cancer Res Clin Oncol , vol.130 , pp. 623-625
    • Terpos, E.1    Politou, M.2    Rahemtulla, A.3
  • 12
    • 18844381179 scopus 로고    scopus 로고
    • Proteasome: An emerging target for cancer therapy
    • Zavrski I, Jakob C, Schmid P, et al. Proteasome: an emerging target for cancer therapy. Anti-Cancer Drug 2005; 23:475-481.
    • (2005) Anti-Cancer Drug , vol.23 , pp. 475-481
    • Zavrski, I.1    Jakob, C.2    Schmid, P.3
  • 13
    • 2242432619 scopus 로고    scopus 로고
    • Tumour lysis syndrome in myeloma
    • Sonneveld P. Tumour lysis syndrome in myeloma. Neth J Med 2002; 60:263.
    • (2002) Neth J Med , vol.60 , pp. 263
    • Sonneveld, P.1
  • 14
    • 0032748385 scopus 로고    scopus 로고
    • Antitumor activity of thalidomide in refractory multiple myeloma
    • Singhal S, Mehra J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
    • (1999) N Engl J Med , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehra, J.2    Desikan, R.3
  • 15
    • 1842555343 scopus 로고    scopus 로고
    • Tumor lysis syndrome in a multiple myeloma treated with thalidomide
    • Fuente N, Mañe JM, Barcelo R, et al. Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Ann Oncol 2004; 15:537-540.
    • (2004) Ann Oncol , vol.15 , pp. 537-540
    • Fuente, N.1    Mañe, J.M.2    Barcelo, R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.